Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

First International Summit on Interventional Pharmacoeconomics

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Opportunities to Optimize Cancer Policies Panel Discussion

Oct

Today In Oncology

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Opportunities to Optimize Cancer Policies Panel Discussion

Depression Increases Cancer-Specific Mortality Risks in Common Cancers

Real-World Data Indicate Lower Adherence Rates for Breast Cancer Endocrine Therapy When Radiation Therapy Is Omitted

SYMPRO-Lung: Could Weekly PRO Symptom Monitoring Improve Survival Outcomes in Any-Stage Lung Cancer?

Mindfulness and Tai Chi May Improve Symptoms After Cancer Treatment

Cleveland Clinic to Host Second Annual AI Summit for Health-Care Professionals